EPS Reference Time Actual Consensus Previous
2026-10-29 FY2026Q3 AM 2.67 2.54 3.09
2026-08-06 FY2026Q2 AM 2.37 1.95 1.60
2026-05-07 FY2026Q1 AM 1.63 1.82 1.33
2026-02-26 FY2025Q4 PM 2.02 1.49 1.27
2025-11-06 FY2025Q3 AM 3.09 1.93 1.84



Peers Price Chg Day Year Date
Agenus 6.29 -0.44 -6.54% 45.60% Nov/16
Amgen 462.32 -3.35 -0.72% 35.30% Nov/16
Anika Therapeutics 12.92 -0.48 -3.58% 33.89% Nov/16
Arrowhead Research 44.21 -3.57 -7.47% 10.11% Nov/16
Baxter International 25.54 -0.27 -1.05% 43.73% Nov/16
Bristol-Myers Squibb 62.93 -0.50 -0.79% 34.44% Nov/16
Enanta Pharmaceuticals 10.67 -0.32 -2.91% -16.77% Nov/16
Gilead Sciences 167.58 -0.50 -0.30% 35.05% Nov/16
GlaxoSmithKline 1,886.00 -43.50 -2.25% 5.54% Nov/17
Glaxosmithkline 50.41 -0.25 -0.49% 6.85% Nov/16

Indexes Price Day Year Date
USND 24510 -626.52 -2.49% 7.93% Nov/16
US Index 400 3628 -54.01 -1.47% 15.31% Nov/16

Ligand Pharmaceuticals traded at $301.71 this Monday November 16th, decreasing $7.08 or 2.29 percent since the previous trading session. Looking back, over the last four weeks, Ligand Pharmaceuticals lost 1.49 percent. Over the last 12 months, its price rose by 49.84 percent. Looking ahead, we forecast Ligand Pharmaceuticals to be priced at 301.84 by the end of this quarter and at 281.92 in one year, according to Trading Economics global macro models projections and analysts expectations.

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company. The Company is focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company's technology includes Captisol Technology, OmniAb Technologies (OMT), Icagen Ion Channel Technology Platform, Pelican Expression Technology platform and Liver Targeting Prodrug (LTP) Technology to assist companies in their work toward securing prescription drug and biologic approvals. It has partnerships and license agreements with over 130 pharmaceutical and biotechnology companies and over 300 programs that are in various stages of commercialization, development or research and are fully funded by its collaboration partners and licensees. Its partners and licensees have programs in clinical development targeting seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney disease, among others.